Beijing-Sana
The China National Biotechnology Group announced that it is expected to complete the clinical trials of the inactivated vaccine for Covid 19 and prepare for its launch early in the end of this year or early next year.
Xinhua quoted the company as saying today that "more than 2,000 people have received vaccines and clinical data have proven their safety and efficacy, which indicates that adverse reactions are much less than other similar products."
To increase manufacturing capacity, the company has built a large production unit in Beijing that meets the high requirements of biosafety protection.
The unit will be able to produce 100 to 120 million doses of inactivated Covid 19 vaccine annually once mass production begins.
